The global in-vitro colorectal cancer screening tests market size was USD 940 million in 2023, calculated at USD 970 million in 2024 and is expected to be worth around USD 1,310 million by 2034. The market is slated to expand at 3.06% CAGR from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: In-vitro Colorectal Cancer Screening Tests Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2024-2034
8.1.1. Fecal Occult Blood Test
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. CRC DNA Screening Test
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Biomarker Test
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. In-vitro Colorectal Cancer Screening Tests Market, by End-user, 2024-2034
9.1.1. Clinics
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Hospital
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Diagnostic Laboratories
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.1.2. Market Revenue and Forecast, by End-user (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End-user (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End-user (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.2. Market Revenue and Forecast, by End-user (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End-user (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End-user (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End-user (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End-user (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.2. Market Revenue and Forecast, by End-user (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End-user (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End-user (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End-user (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End-user (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.2. Market Revenue and Forecast, by End-user (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End-user (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End-user (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End-user (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End-user (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.5.2. Market Revenue and Forecast, by End-user (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End-user (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End-user (2021-2034)
11.1. Abbott Molecular
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. BioMarCare Technologies
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Eiken Chemical
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Epigenomics AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Exact Sciences Corporation
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Immunostics
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novigenix
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. OncoCyte Corporation-Bio time
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Quest Diagnostics
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Randox Laboratories
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample